Sequencing

Executive Summary

Sequencing.com is a direct-to-consumer and B2B2C genetic information company that differentiates itself through whole genome sequencing (WGS) rather than genotyping, and a 'Privacy Forever' guarantee. By sequencing 100% of a customer's genome once and continuously reanalyzing it against the latest research, the company provides lifelong, actionable health intelligence on a subscription basis. This approach addresses a key limitation of competitors like 23andMe, which use genotyping arrays that cover only a fraction of the genome and are not updated. With a strong emphasis on data security and an expanding library of health reports, Sequencing.com is positioning itself as a trusted, comprehensive platform for personal genomics. However, the company operates in a fragmented market with regulatory and reimbursement challenges, and its B2B2C model requires scaling partnerships to drive adoption. The management team is lean and operational, but financial details and stage remain undisclosed, limiting visibility into near-term growth.

Upcoming Catalysts (preview)

• Q4 2026FDA clearance for select clinical-grade health reports (e.g., pharmacogenomics)40% success
• Q3 2026Major B2B partnership with a national health system or insurance payer50% success
• Q2 2027Series B or C funding round to expand marketing and infrastructure60% success